European Foundation for the Study of Diabetes

The Research Foundation of the European Association for the Study of Diabetes

Request for Applications (RFA)

**European Foundation for the Study of Diabetes (EFSD)
Juvenile Diabetes Research Foundation International (JDRF)
and
Novo Nordisk A/S**

ANNOUNCING UP TO EURO 2.25 MILLION IN ADDITIONAL FUNDS FOR RESEARCH ON TYPE 1 DIABETES IN EUROPE

**In the framework of the EFSD / JDRF / Novo Nordisk European Programme
in Type 1 Diabetes Research**

Background

The European Association for the Study of Diabetes (EASD) was founded in Montecatini, Italy, in 1965. In 1999, the Association created the *European Foundation for the Study of Diabetes (EFSD)*. The aims of EFSD are to encourage and support research in the field of diabetes, to rapidly diffuse acquired knowledge and to facilitate its application.

The mission of *Juvenile Diabetes Research Foundation International (JDRF)* is to find a cure for diabetes and its complications through the support of research. JDRF was founded in 1970 by parents of children with diabetes who were convinced that the disease could be cured. JDRF gives more money to diabetes research than any other non-profit, non-governmental health agency in the world.

Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Headquartered in Denmark, Novo Nordisk has companies and information offices in more than 60 countries.

Plan and Research Focus

The partners have established the EFSD / JDRF / Novo Nordisk Programme in Type 1 Diabetes Research to foster multi-disciplinary research targeted at

finding a cure for Type 1 diabetes and its complications.

The specific goals of the Programme are to:

- i.) promote the highest quality of basic and clinical biomedical research in Europe and its associated countries applicable to Type 1 diabetes;
- ii.) expedite the practical application of scientific advances in our understanding of the etiology, pathogenesis, treatment and prevention of Type 1 diabetes and its complications;
- iii.) encourage clinical translational research bridging the bench and the bedside;
- iv.) increase awareness about Type 1 diabetes research throughout Europe.

To achieve its goals and objectives the Programme is issuing a request for applications (RFA) for research grants. The EFSD / JDRF / Novo Nordisk European Programme in Type 1 Diabetes Research will accept applications within any area of basic or clinical diabetes research focusing on *Type 1 diabetes and its complications*.

Funding

Up to Euro 2.25 million will be made available, over three years, for Focused Research Grants. Research

will be performed in Europe and its associated countries. The grants will be distributed as follows:

2004 – Up to eight grants, each of Euro 100,000

2005 – Up to eight grants, each of Euro 100,000

2006 – Up to eight grants, each of Euro 100,000

Mechanisms of Support and Review

Research will be supported through the award of fixed sum grants, each of Euro 100,000. The duration of each award may be one year or longer, depending upon the needs of the project and as justified in the application, so long as the total budget does not exceed the fixed sum of Euro 100,000, payable in the first year and in one installment.

Up to eight awards will be granted annually for the period of three years. Applications for an EFSD / JDRF / Novo Nordisk Programme Grant are invited from single non-profit institutions or groups of affiliated institutions from Europe and associated countries. Applications will be subject to scientific review by a specialised and independent ad hoc committee. Funding will require approval by a joint EFSD, JDRF and Novo Nordisk Board convened for this purpose. Anticipated dates for application review and funding approval are given in the schedule at the end of this document.

Research Grant Applications

Applications for research grants may be subjected to pre-review (or triage) procedures. In this event, any application rejected at pre-review will not be subject to a complete scientific review.

The deadlines for receipt of research grant applications are given in the schedule at the end of this document.

For the purpose of this Programme, the budget of the research grants is limited to Euro 100,000 per annum. All budgets are to be prepared in Euro. For countries in which the Euro is not yet the common currency, the exchange rate (between the Euro and the local currency in the country where the work is to be performed) used for calculating the Euro budget must be mentioned under "Budget Justification". EFSD, JDRF and Novo Nordisk reserve the right to increase or decrease approved funding in Euro amounts to compensate for any significant change in the exchange rate.

Application forms are available at:
foundation@easd.org

All applications must be prepared on the official forms and completed in strict accordance with the de-

tailed instructions to be found on these forms. In particular, applicants are reminded that any pages in addition to the maximum of 10 allowed for the scientific section of the application will be deleted prior to review. Similarly, no applications using a font or line-spacing smaller than defined in the instructions will be considered for review. Additional material (in the form of an appendix, attachments, reprints, etc.) is not acceptable and will not be sent to reviewers.

Applications should be submitted by 5 April 2004 (date of receipt in Düsseldorf) to:

Viktor Jörgens, M.D., Executive Director
European Foundation for the Study of Diabetes
Rheindorfer Weg 3
D-40591 Düsseldorf, Germany

Review Considerations

Completed applications will be evaluated in accordance with the criteria stated below for scientific / technical merit by an appropriate scientific committee convened by EFSD.

Review criteria are as follows:

- **Significance:** Does the study address an important problem? If the aims of the application are achieved, how will scientific knowledge be advanced? What will be the effect of the proposed studies on the concepts or methods that drive this field?
- **Approach:** Are the conceptual framework, design, methods and analyses adequately developed, well integrated and appropriate to the aims of the project? Does the applicant acknowledge potential problem areas and consider alternative tactics?
- **Innovation:** Does the project employ novel concepts, approaches or methods? Are the aims original and innovative? Does the project challenge existing paradigms or develop new methodologies or technologies?
- **Investigator:** Is the investigator appropriately trained and well suited to carry out this work? Is the work proposed appropriate to the experience level of the principal investigator and other researchers (if any)?
- **Environment:** Does the scientific environment in which the work will be done contribute to the probability of success? Do the proposed experiments take advantage of unique features of the scientific environment or employ useful collaborative arrangements? Is there evidence of institutional support?
- **Relevance:** A brief statement of the impact of the proposed study on Type 1 diabetes mellitus.

Reporting Requirements

All investigators funded by this Programme are required to submit an annual scientific progress report and an annual expenditure report for the duration of the project. Investigators must provide EFSD with early notice of papers accepted for publication and must acknowledge the support of the Programme in such papers by use of the sentence: "This work was made possible by a grant from the EFSD / JDRF / Novo Nordisk European Programme in Type 1 Diabetes Research".

Competitive Renewal

Applications for renewal of an EFSD / JDRF / Novo Nordisk Type 1 Diabetes Research Grant will be ac-

cepted on a competitive basis, with the same review process as described in this announcement. Such applications will thus be considered in the same fashion as all other new applications received for review and without any special priority.

Schedule

Announcement:	February issue of <i>Diabetologia</i>
Application Deadline:	5 April 2004
Anticipated Award:	June 2004

EASD**EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES**

ASSOCIATION EUROPEENNE POUR L'ETUDE DU DIABETE · EUROPÄISCHE GESELLSCHAFT FÜR DIABETOLOGIE

Rheindorfer Weg 3 · D-40591 Düsseldorf · Germany · Tel: +49-211-7 58 46 90 · Fax: +49-211-75 84 69 29

E-mail: secretariat@easd.org · Homepage: <http://www.easd.org>**EASD****News Section
2/2004****JOSEPH HOET RESEARCH AWARD – 2004**

The DPSG (Diabetic Pregnancy Study Group, EASD) announces the Second Joseph Hoet Research Award (JHRA) to be given on the occasion of the Annual Meeting of the Study Group (Coimbra, Portugal), 9–12 September, 2004.

The award will consist of a commemorative plaque and a diploma-certificate, travel expenses and Euro 7.000 for the awardee, with the support of HemoCue AB. The call for nominations is open, on a competitive basis, for excellence of research in the field of Diabetes and Pregnancy, under the following conditions:

1. The candidate must be younger than 45 years on 1 January of the year of the award.
2. There is no restriction concerning the nationality of candidates.
3. The JHRA will be given in relation to research of excellence in the field of Diabetes and Pregnancy (Basic or Clinical) manifested by publications with important contribution to the advancement of knowledge in the field.
4. **Before 23 April in the year of the Award**, the Chairman of the DPSG should receive all documents for nomination as attachments to an email. This shall include the candidate's Curriculum Vitae with complete bibliography, the most relevant publications (not more than 6; as .pdf-files) and a statement by the candidate, explaining the manner in which the research and the publications have contributed to the advancement of knowledge in the area of Diabetes and Pregnancy. Such a statement should not exceed 1.000 words. Additional letters

of support of relevant authorities in the field of Diabetes and Pregnancy may be also enclosed (.pdf-files). **Renewal of application** is possible.

5. The jury to decide on the award will be formed by the four active members of the DPSG Board plus another member, chosen by the official representatives of HemoCue AB from among ordinary/honorary DPSG members or, if not European, an ordinary/honorary member of the International Association of Diabetic and Pregnancy Study Groups (IADPSG). Only in exceptional cases, if the jury cannot make a final choice between 2 final candidates, with almost identical evaluation, the DPSG Chair's vote will be decisive.
6. The recipient of the prize is expected to give the **Joseph Hoet Lecture** during the annual DPSG meeting, describing his/her most important scientific achievements, and is also expected to write a respective review article for publication in *Diabetologia* (if this is accepted by the Editorial office of the journal).
7. Applications should be addressed to the Chairman of DPSG:

Prof. Gernot Desoye

Clinic of Obstetrics and Gynaecology

Medical University

Auenbruggerplatz 14

A-8036 Graz, Austria

E-mail: gernot.desoye@kfunigraz.ac.at

Phone: +43-316-385-4605

Fax: +43-316-385-2506

Announcements

XV International Symposium on Drugs Affecting Lipid Metabolism

Venice, Italy, 24–27 October 2004

The Symposium is sponsored by the National Heart, Blood, and Lung Institute, the International Atherosclerosis Society, the Weill Medical College of Cornell University and is organised by the Giovanni Lorenzini Medical Foundation (Milan, Italy and Houston, USA).

The purpose of the meeting is to update researchers and clinicians on recent research regarding the effect of drugs on lipid metabolism and the state of the art in the clinical treatment of atherosclerosis and related diseases, thereby enhancing patient outcome.

The scientific programme will include:

- Plenary sessions
- Workshops
- Sponsored symposia
- Oral communications
- Poster sessions for submitted papers

The chairpersons are:

- A. M. Gotto, Jr. (USA)
- R. Paoletti (Italy)

The scientific secretaries are:

- A. L. Catapano (Italy)
- C. M. Ballantyne (USA)

Call for abstracts (oral or poster presentations):

Abstracts must be sent to the Scientific Organising Secretariat by **15 May 2004**.

For further information please contact the main secretariat office:

DALM 2004
Fondazione Giovanni Lorenzini
Medical Science Foundation
Via A. Appiani, 7
I-20121 Milan
Italy
Tel: +39-02-29006267
Fax: +39-02-29007018
E-mail: dalm@lorenzinfoundation.org
Website: www.lorenzinfoundation.org

For USA and Canada:

DALM 2004
Giovanni Lorenzini
Medical Foundation
6535 Fannin, M.S. A-601
Houston, Texas 77030
USA
Tel: +1-713-7970401
Fax: +1-713-7968853
E-mail: dalm@bcm.tmc.edu
Website: www.lorenzinfoundation.org

VI International Congress on Amino-acid/protein metabolism in health and disease

Milan, Italy, 25–27 March 2004

The Chairman of the meeting is:
Livio Luzi, M.D., Milan, Italy

The Local Scientific Committee consists of:
Pierpaolo De Feo, M.D., Milan, Italy
Giulio Marchesini, M.D., Bologna, Italy
Paolo Tessari, M.D., Milan, Italy

For further information, please contact:

Organising Secretariat
Stefania Grassi
San Raffaele Congress Centre
Via Olgettina 58
I-20132 Milan
Italy
Tel: +39-02-26433700
Fax: +39-02-26433754
E-mail: congress@spr.it
Website: www.spr.it

8th International Symposium on the Maillard Reaction

Charleston, S.C., USA, 28 August–1 September 2004

This milestone meeting will mark the 25th anniversary of the first Maillard Symposium organised by a group of food chemists and biomedical scientists in Lund, Sweden in 1979. That conference, like those that have followed every 3–4 years, was convened because of the increasing recognition of the role of the Maillard or browning reaction in both food chemistry and living systems. In food technology the Maillard reaction plays a central role in the development of colour, aroma, flavor, texture and nutritional value of cooked and processed foods. In humans, the Maillard reaction contributes to the increased fluorescence, colour and cross-linking of extracellular proteins during normal aging. Acceleration of these reactions is implicated in the development of diabetic complications and in inflammatory processes linked to neurodegenerative diseases and atherosclerosis.

For detailed information about the meeting, including abstract submission, a call for papers and deadlines, please visit our website at <http://maillard.sc.edu> or e-mail the organising committee at maillard@mail.chem.sc.edu

Request for Applications Clinical Islet Transplantation: Data Coordinating Center

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Institute of Allergy and Infectious Diseases (NIAID) invite applications for a Data Coordinating Center (DCC) to participate in a consortium of investigators and institutions that will perform clinical studies of islets in patients with Type 1 diabetes mellitus.

Letter of Intent receipt date: **16 March 2004**

Application receipt date: **13 April 2004**

For more information please check the following web site:

<http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-04-004.html>

Request for Applications Progression of Cardiovascular Disease (CVD) in patients with Type 1 diabetes

The National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Diabetes, Digestive and Kidney diseases (NIDDK) invite investigator-initiated applications for basic and clinical studies to enhance our understanding of the onset and progression of cardiovascular disease (CVD) in patients with Type 2 diabetes.

Letter of Intent receipt date: **24 February 2004**

Application receipt date: **24 March 2004**

For more information please check the following website:

<http://grants2.nih.gov/grants/guide/rfa-files/RFA-HL-04-013.html>

<p>EASD News Section 2/2004 DOI 10.1007/s00125-004-1326-6</p>